KalVista Pharmaceuticals/$KALV
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About KalVista Pharmaceuticals
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Ticker
$KALV
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
150
ISIN
US4834971032
Website
KALV Metrics
BasicAdvanced
$596M
-
-$3.72
0.76
-
Price and volume
Market cap
$596M
Beta
0.76
52-week high
$15.50
52-week low
$7.30
Average daily volume
939K
Financial strength
Current ratio
10.438
Quick ratio
10.252
Long term debt to equity
2.989
Total debt to equity
72.525
Interest coverage (TTM)
-63.84%
Profitability
EBITDA (TTM)
-180.521
Effective tax rate (TTM)
-2.47%
Management effectiveness
Return on assets (TTM)
-58.15%
Return on equity (TTM)
-150.50%
Valuation
Price to book
4.09
Price to tangible book (TTM)
4.09
Price to free cash flow (TTM)
-4.416
Free cash flow yield (TTM)
-22.64%
Free cash flow per share (TTM)
-271.27%
Growth
Earnings per share change (TTM)
18.42%
3-year earnings per share growth (CAGR)
6.87%
What the Analysts think about KALV
Analyst ratings (Buy, Hold, Sell) for KalVista Pharmaceuticals stock.
Bulls say / Bears say
KalVista's lead candidate, sebetralstat, has received FDA acceptance for its New Drug Application, with a PDUFA goal date set for June 17, 2025, indicating potential market entry in the near future. (businesswire.com)
The company has secured $160 million in funding through synthetic royalty financing and equity offerings, providing financial stability to support the commercialization of sebetralstat. (businesswire.com)
Analysts from HC Wainwright and Needham & Company LLC have reiterated 'buy' ratings for KalVista, with price targets of $20.00 and $28.00 respectively, reflecting confidence in the company's growth prospects. (americanbankingnews.com)
KalVista reported no revenue for the three months ended October 31, 2024, highlighting its current reliance on future product approvals for income generation. (businesswire.com)
General and administrative expenses increased to $29.2 million for the same period, primarily due to pre-commercial planning activities, which could strain financial resources if product launches are delayed. (businesswire.com)
The company's stock price has experienced volatility, with a 52-week range between $7.21 and $16.88, indicating potential investor uncertainty regarding its future performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
KALV Financial Performance
Revenues and expenses
KALV Earnings Performance
Company profitability
KALV News
AllArticlesVideos
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 days ago
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
Business Wire·1 week ago
US FDA extends review of KalVista's swelling disorder drug due to heavy workload
Reuters·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KalVista Pharmaceuticals stock?
KalVista Pharmaceuticals (KALV) has a market cap of $596M as of July 04, 2025.
What is the P/E ratio for KalVista Pharmaceuticals stock?
The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of July 04, 2025.
Does KalVista Pharmaceuticals stock pay dividends?
No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next KalVista Pharmaceuticals dividend payment date?
KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.
What is the beta indicator for KalVista Pharmaceuticals?
KalVista Pharmaceuticals (KALV) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.